Published in Mol Ther on November 01, 2005
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci (2009) 0.92
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 0.89
Gene therapy of liver cancer. World J Gastroenterol (2006) 0.86
Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. PLoS One (2012) 0.85
Cancer immunotherapy: dendritic-cell vaccines on the move. Nature (2015) 0.83
A targeted IL-15 fusion protein with potent anti-tumor activity. Cancer Biol Ther (2015) 0.81
Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer. Am J Immunol (2009) 0.81
Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol (2007) 0.81
Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma. Oncolytic Virother (2013) 0.80
Simian virus 40 vectors for pulmonary gene therapy. Respir Res (2007) 0.78
Magnetic resonance imaging-guided adoptive cellular immunotherapy of central nervous system tumors with a T1 contrast agent. Magn Reson Med (2009) 0.78
microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res (2009) 2.80
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res (2006) 2.38
Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases. Nature (2008) 2.37
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. Nucleic Acids Res (2009) 2.14
Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. J Mol Biol (2005) 2.04
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res (2009) 1.95
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95
Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res (2008) 1.94
Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91
Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology (2008) 1.87
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75
Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria. Hum Gene Ther (2013) 1.62
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc Natl Acad Sci U S A (2003) 1.55
Adenovirus virus-associated RNA is processed to functional interfering RNAs involved in virus production. J Virol (2006) 1.53
MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells (2011) 1.49
Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant. J Surg Res (2012) 1.45
Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology (2005) 1.44
Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology (2011) 1.44
Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. PLoS One (2012) 1.43
Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology (2010) 1.41
Methionine adenosyltransferase II beta subunit gene expression provides a proliferative advantage in human hepatoma. Gastroenterology (2003) 1.40
Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology (2012) 1.38
The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol (2009) 1.36
Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J Virol (2006) 1.32
The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) (2009) 1.31
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 1.29
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25
SimB16: modeling induced immune system response against B16-melanoma. PLoS One (2011) 1.25
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol (2005) 1.23
Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology (2008) 1.23
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 1.22
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2011) 1.22
Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res (2008) 1.21
The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology (2008) 1.20
Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol (2002) 1.19
Novel role for amphiregulin in protection from liver injury. J Biol Chem (2005) 1.19
Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus. Nucleic Acids Res (2010) 1.19
Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol (2005) 1.18
Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 1.18
Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol (2010) 1.17
In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther (2003) 1.17
Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology (2006) 1.16
Homing endonucleases: from basics to therapeutic applications. Cell Mol Life Sci (2010) 1.16
Requirements for gene silencing mediated by U1 snRNA binding to a target sequence. Nucleic Acids Res (2008) 1.16
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res (2006) 1.14
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant (2003) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
Gene therapy of cancer based on interleukin 12. Curr Gene Ther (2005) 1.13
Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology (2010) 1.12
Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab (2011) 1.12
Anion exchanger 2 is essential for spermiogenesis in mice. Proc Natl Acad Sci U S A (2003) 1.11
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol (2009) 1.09
A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine (2003) 1.08
The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol (2007) 1.08
Adenovirus VA RNA-derived miRNAs target cellular genes involved in cell growth, gene expression and DNA repair. Nucleic Acids Res (2009) 1.08
De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl (2005) 1.07
Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol (2007) 1.06
Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res (2011) 1.06
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res (2013) 1.05
Gene therapy of cancer with interleukin-12. Curr Pharm Des (2003) 1.04
A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol (2010) 1.03
Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther (2011) 1.03
A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS One (2007) 1.03
Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning. J Exp Med (2006) 1.02
Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol (2007) 1.02
Expression of Wilms' tumor suppressor in the liver with cirrhosis: relation to hepatocyte nuclear factor 4 and hepatocellular function. Hepatology (2003) 1.01
Crystal structure of I-DmoI in complex with its target DNA provides new insights into meganuclease engineering. Proc Natl Acad Sci U S A (2008) 1.01
Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol Dis (2007) 1.01
Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer (2005) 1.01
Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res (2002) 1.01
Structure of the AvrBs3-DNA complex provides new insights into the initial thymine-recognition mechanism. Acta Crystallogr D Biol Crystallogr (2013) 1.01
Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells: molecular mechanisms and functional implications. Proteomics (2010) 1.01